Completion of Manufacturing of Drug Product for C-Diff Trial
Filed with ASX · · 3 pages · English
In the deck
Earlier from Immuron
- IMC Form F1 - US Registration Statement (Prelim. Prospectus)
- Positive Results of IMM-124E in Acute Colitis Studies
- Close of Recruitment of Phase II NASH Trial
- Appendix 4D - Half Year Report and Accounts - Dec 2016
- Immuron Completes Phase II NASH Clinical Trial Recruitment
Later from Immuron
- IMC Expands Agreement with US Army-3 Additional Therapeutics
- NASDAQ Listing on Hold Pending NASH Interim Analysis Results
- Immuron Secures $1.5M R&D Cash Advance Loan Funding
- Travelan Increases Industry Presence - Conf & Sales Update
- IMC Prices US IPO and NASDAQ Listing Raising USD$6.1M
Follow Immuron into a list and get an email when it puts out news.
Follow Immuron